MKI67 and cervical carcinoma: Similarities with several studies in the sensitivity levels for detection HSIL (CIN2+) obtained in our screening model 1 were noted, including the study of the New Technologies for Cervical Cancer Screening group [24] (81.8%), the report of the Wentzensen et al. [20] (86.8%) in a comparable to our size study and the ATHENA sub-study trial—similarities with our results were observed only in the group with p16/Ki67 triaging N16/N18 HPV-positive test results (82.8%) [15].